ScholarDeck

Cohort studyPediatric blood & cancer · 2026

Prevalence of 21 Physician-Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study.

Lane Collier, Brittany Grantham, Camilla Grud Nielsen … Rachel Conyers

PediatricsCohort study

Nearly a quarter of childhood acute lymphoblastic leukemia patients experienced severe toxicities.

Prevalence of 21 Physician-Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study.

Lane Collier et al. · Pediatric blood & cancer · 2026

Background

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with an overall survival now surpassing 90% in developed countries.

Methods

Retrospective cohort study.

22.6%

Results

patients with childhood blood cancer who experienced serious side effects from treatment

More results

We identified 345 patients who received primary ALL treatment at the Royal Children's Hospital, meeting the inclusion criteria of this study.

The median age at Dx was 4 years (QR 3-9), and 161 patients (46.7%) were female.

More results

The most common toxicities observed are mental health concerns (9.6%), osteonecrosis (6.7%), and paralytic, neuropathic, myopathic, and movement disorders (4.1%).

“

Conclusion · 1 of 3

Our study reveals that 22.6% of patients with ALL experienced severe toxicities according to the STFS endpoint.

Conclusion · 2 of 3

The prominence of mental health concerns, osteonecrosis, and various movement disorders highlights the diverse nature of these toxicities.

Conclusion · 3 of 3

Given their severity and breadth, ongoing surveillance and intervention should be incorporated into standard care.

Post

Prevalence of 21 Physician-Defined Severe Toxicities Following Childhood Acute Lymphoblastic Leukemia Treatment: Australian Retrospective Cohort Study.

Nearly a quarter of childhood acute lymphoblastic leukemia patients experienced severe toxicities.

Related papers